Eduardo Mannarino Correia

Eduardo Mannarino Correia

Auto-generated profile, based on publicly available information

Eduardo Mannarino Correia

Cell and Gene Therapy Program - Research Coordination, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of the Brazilian Chemical Society
Verified
Journal Article
Closed access
MGMônica Gomes
Mônica Gomes
ECEduardo Correia
Eduardo Correia
MGMax Gomes
Max Gomes
CCClaudio Cirne-Santos
Claudio Cirne-Santos
CBCaroline Barros
Caroline Barros
FSFernando de C. da Silva
Fernando de C. da Silva
The cariogenic processes are mainly caused by the bacterium Streptococcus mutans (S. mutans) and consist of the demineralization of the tooth that occurs when the acid production overcomes the natural repair or if a problem occurs in the last one. In this work, we performed the synthesis of twenty-one 1,4-naphthoquinones tethered to 1,2,3-1H-triazoles (8a-8k and 9a-9j), antibacterial evaluation against the S. mutans in vitro and the acute toxicity of the better ones in vivo. We observed strong inhibition results in the disc diffusion test ranging, the halos of inhibitions, from 18.66 (± 0.57) to 29 (± 2.64) mm, and good values in the minimum inhibitory concentration (5 to 50 μg), for the compounds 9e, 9h, 9i and 9j. Furthermore, they do not have a cytotoxic effect at the concentrations tested. Besides that, in the in vivo test, they show some slight alteration in the histopathological analyses and the biochemistry. Thus, we found four potential candidates to become instruments for the treatment of cavities.

19 February 2025 in Cancer Research
Verified
Journal Article
Closed access
MCMaria Leticia Rodrigues Carvalho
Maria Leticia Rodrigues Carvalho
CAClara de Oliveira Andrade
Clara de Oliveira Andrade
MCMariela Pires Cabral-Piccin
Mariela Pires Cabral-Piccin
GKGabriela Sarti Kinker
Gabriela Sarti Kinker
Glauco Akelinghton Freire VItielloGlauco Akelinghton Freire VItiello
Glauco Akelinghton Freire VItiello
TMTiago Medina
Tiago Medina
Chimeric antigen receptor (CAR) T-cell therapy is increasingly being adopted as a clinical modality for patients with relapsed/refractory hematologic malignancies. Despite the clinical efficacy of CAR T-cell therapy, a considerable fraction of patients still relapse during the first months following CAR T-cell infusion. The limited CAR T-cell efficiency is thought to relate to epigenetic mechanisms involved in T-cell suppression and dysfunction. In this study, screening of multiple epigenetic inhibitors revealed that targeting polycomb repressive complex 2 (PRC2) consistently induced the development of granzyme B+ effector memory CD8 T cells. Notably, PRC2 inhibition also promoted the long-term persistence of granzyme B+ effector memory 19BBζ CAR T cells and enhanced sustainably their antitumor activity both in vitro and in vivo. Consistent with their long-lasting antitumor activity, PRC2-inhibited 19BBζ CAR T cells did not exhibit signs of exhaustion over time. Furthermore, TCR restimulation along with PRC2 inhibition promoted the differentiation of patient-derived anti-CD19 effector memory CAR T cells with enhanced cytotoxic features and elicited potent antitumor responses. In line with this, the gene signature derived from in-house PRC2-inhibited 19BBζ CAR T cells was enriched in tisagenlecleucel BBζ CAR T-cell therapy responders with large B-cell lymphoma. Collectively, our results demonstrated that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR T cells against hematologic malignancies. Significance: Selective inhibition of PRC2 endows 19BBζ CAR T cells with cytotoxic and effector memory features that are associated with improved antitumor activity and better response to CAR T-cell therapy.